Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001898478 | SCV002159676 | likely benign | not provided | 2021-12-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004041516 | SCV004928069 | uncertain significance | Inborn genetic diseases | 2024-02-27 | criteria provided, single submitter | clinical testing | The c.2174G>A (p.R725Q) alteration is located in exon 19 (coding exon 19) of the CLCN2 gene. This alteration results from a G to A substitution at nucleotide position 2174, causing the arginine (R) at amino acid position 725 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005038456 | SCV005665025 | uncertain significance | Epilepsy, idiopathic generalized, susceptibility to, 11; Familial hyperaldosteronism type II; Leukoencephalopathy with mild cerebellar ataxia and white matter edema | 2024-01-10 | criteria provided, single submitter | clinical testing |